BiotechTube

Gabapentin + placebo

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease, Neuropathic Pain

Trial Timeline

Apr 1, 2012 → Jun 1, 2014

NCT ID
NCT01588314

About Gabapentin + placebo

Gabapentin + placebo is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01588314. Target conditions include Fabry Disease, Neuropathic Pain.

What happened to similar drugs?

9 of 20 similar drugs in Fabry Disease were approved

Approved (9) Terminated (4) Active (10)
✅agalsidase betaSanofiApproved
✅Fabrazyme (agalsidase beta)SanofiApproved
✅agalsidase betaSanofiApproved
✅AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
✅Agalsidase betaSanofiApproved
✅agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
✅Agalsidase betaSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01588314Phase 2Withdrawn

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
38
Fabrazyme (agalsidase beta)SanofiPhase 2
35
Venglustat (GZ402671) + PlaceboSanofiPhase 3
44
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
27
agalsidase betaSanofiApproved
35
TropicamideSanofiPre-clinical
26
Fabrazyme (agalsidase beta)SanofiApproved
35
agalsidase betaSanofiApproved
43
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
43
Agalsidase betaSanofiApproved
43
GZ/SAR402671SanofiPhase 2
35
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
35
Fabrazyme (agalsidase beta)SanofiPhase 3
40
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
44
IohexolSanofiPhase 1
21
GZ/SAR402671SanofiPhase 2
35
Fabrazyme (agalsidase beta)SanofiPhase 2
35
Agalsidase betaSanofiApproved
43
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
43
Agalsidase beta + Agalsidase betaSanofiPhase 3
40